Prehospital COVID Therapy Effective in Rheumatic Disease Patients

Patients with rheumatic disease and SARS-CoV-2 infection who received outpatient treatment fared better than similar patients who did not receive treatment, but COVID-19 rebound was not infrequent in patients who received outpatient treatment.

Related Keywords

Boston ,Massachusetts ,United States ,United Kingdom ,London ,City Of ,Katie Bechman ,King College London ,Medscape Coronavirus Resource Center ,Brigham Integrated Health Care System ,Harvard Medical School ,Coronavirus Resource ,Medscape Medical ,Outpatient Treatment ,Important Tool ,Patients With Rheumatic ,Mass General ,Confounding Factors ,College London ,Covid 19 Treatment ,Coronavirus ,019 Novel Coronavirus ,019 Ncov ,Uhan Coronavirus ,Uman Coronavirus Hku1 ,Uman Coronavirus Oc43 ,Cov Oc43 ,Uman Coronavirus 229e ,Cov 229e ,Rheumatic Disease ,Rheumatoid Arthritis ,A ,Antiviral ,Amciclovir ,Alacyclovir ,Monoclonal Antibody ,Etuximab ,Ituximab ,Covid 19 Vaccine ,Coronavirus Vaccine ,Clinical Research ,Clinical Trials ,Linical Studies ,Medical ,